PMID- 36517442 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230104 IS - 0253-3758 (Print) IS - 0253-3758 (Linking) VI - 50 IP - 12 DP - 2022 Dec 24 TI - [Impact of interventional therapy on top of standard drug therapy on left ventricular structure and function in HFrEF patients complicating with middle aortic syndrome caused by Takayasu arteritis]. PG - 1207-1213 LID - 10.3760/cma.j.cn112148-20221014-00804 [doi] AB - Objective: To evaluate the impact of interventional therapy on top of drug therapy on cardiac function and structure in heart failure with reduced ejection fraction (HFrEF) patients complicating with middle aortic syndrome caused by Takayasu arteritis (TA-MAS). Methods: It was a retrospective longitudinal study. The data of patients with TA-MAS and HFrEF, who received interventional therapy on top of drug therapy in Fuwai Hospital from January 2010 to September 2020, were collected and analyzed. Baseline clinical data (including demographic data, basic treatment, etc.) were collected through the electronic medical record system. Changes of indexes such as New York Heart Association (NYHA) classification, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), left ventricular mass index (LVMI) before and after therapy were analyzed. Results: A total of 10 patients were collected. There were 8 females in this patient cohort, age was (18.4+/-5.0) years and onset age was (15.3+/-5.0) years. All 10 patients received standard heart failure medication therapy in addition to hormone and/or immunosuppressive anti-inflammatory therapy, but cardiac function was not improved, so aortic balloon dilatation and/or aortic stenting were performed in these patients. The median follow-up was 3.3(1.3, 5.6) years. On the third day after interventional therapy, the clinical symptoms of the 10 patients were significantly improved, NYHA classfication was restored from preoperative Ⅲ/Ⅳ to Ⅱ at 6 months post intervention(P<0.05). Compared with preoperation, NT-proBNP (P=0.028), LVEDD (P=0.011) and LVMI (P=0.019) were significantly decreased, LVEF was significantly increased (P<0.001) at 6 months after operation. Compared with preoperation, NT-proBNP (P=0.016), LVEDD (P=0.023) and LVMI (P=0.043) remained decreased, LVEF remained increased (P<0.001) at 1 year after operation. Conclusion: Results from short and medium term follow-up show that interventional therapy on top of heart failure drug therpay can effectively improve left cardiac function and attenuate cardiac remodeling in patients with TA-MAS comorbid with HFrEF. FAU - Wang, Q AU - Wang Q AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Jiang, X J AU - Jiang XJ AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Dong, H AU - Dong H AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Che, W Q AU - Che WQ AD - Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China. FAU - He, J N AU - He JN AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Chen, Y AU - Chen Y AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Song, L AU - Song L AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Zhang, H M AU - Zhang HM AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. FAU - Zou, Y B AU - Zou YB AD - State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. LA - chi GR - 82170449/National Natural Science Foundation of China/ PT - English Abstract PT - Journal Article PL - China TA - Zhonghua Xin Xue Guan Bing Za Zhi JT - Zhonghua xin xue guan bing za zhi JID - 7910682 RN - 114471-18-0 (Natriuretic Peptide, Brain) RN - 0 (Peptide Fragments) RN - 0 (Cardiovascular Agents) SB - IM MH - Adolescent MH - Child MH - Female MH - Humans MH - Young Adult MH - *Heart Failure/drug therapy/etiology/surgery MH - Longitudinal Studies MH - Natriuretic Peptide, Brain MH - Peptide Fragments MH - Retrospective Studies MH - Stroke Volume MH - *Takayasu Arteritis/complications/drug therapy/surgery MH - Ventricular Function, Left/drug effects MH - Heart Ventricles/drug effects MH - Male MH - Cardiovascular Agents/pharmacology/therapeutic use MH - Angioplasty, Balloon MH - Stents MH - Blood Vessel Prosthesis Implantation EDAT- 2022/12/15 06:00 MHDA- 2022/12/17 06:00 CRDT- 2022/12/14 22:16 PHST- 2022/12/14 22:16 [entrez] PHST- 2022/12/15 06:00 [pubmed] PHST- 2022/12/17 06:00 [medline] AID - 10.3760/cma.j.cn112148-20221014-00804 [doi] PST - ppublish SO - Zhonghua Xin Xue Guan Bing Za Zhi. 2022 Dec 24;50(12):1207-1213. doi: 10.3760/cma.j.cn112148-20221014-00804.